The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome
- 26 February 2004
- journal article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 43 (5) , 854-857
- https://doi.org/10.1016/j.jacc.2003.08.056
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Cholesteryl Ester Transfer Protein Taq I B2B2 Genotype Is Associated With Higher HDL Cholesterol Levels and Lower Risk of Coronary Heart Disease End Points in Men With HDL DeficiencyArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged menAtherosclerosis, 2002
- Association of Cholesteryl Ester Transfer Protein– Taq IB Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease RiskArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary AtherosclerosisNew England Journal of Medicine, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Genetic Bit Analysis: a solid phase method for typing single nucleotide polymorphismsNucleic Acids Research, 1994